Welcome to our dedicated page for Apellis Pharmace SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apellis Pharmaceuticals, Inc. filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company with common stock registered under the Exchange Act. The company’s 8-K reports cover product revenue disclosures for SYFOVRE and EMPAVELI, cash and financial-condition updates, and material agreements related to collaborations, royalty arrangements, financing consents, and strategic transaction activity.
Apellis filings also record governance and compensation matters, including board appointments, director compensation, executive separation and retention plans, and related equity-award provisions. These documents disclose formal corporate actions, capital-structure references, material-event reporting, and the company’s public-company obligations as a Delaware issuer.
Apellis Pharmaceuticals Chief Scientific Officer receives new equity grant. Pascal Deschatelets was awarded 25,840 shares of Apellis common stock on January 28, 2026 as a restricted stock unit grant at a price of $0 per share. These units vest 25% each year over four years, conditioned on continued service. Following this award, he beneficially owns 1,177,222 shares of Apellis common stock held directly.
Apellis Pharmaceuticals’ Chief Research and Development officer Leslie Meltzer reported a stock-based compensation grant. On January 28, 2026, Meltzer received 45,220 shares of Apellis common stock at a price of $0 per share, reflecting a restricted stock unit award.
Following this grant, Meltzer beneficially owns 107,024 shares directly. The award vests 25% each year over four years from the grant date, and vesting is conditioned on continued service with the company.
Apellis Pharmaceuticals reported that Chief Technical Officer Nur Nicholson received a grant of 45,220 shares of common stock on January 28, 2026. The shares were awarded at a price of $0 per share as part of an equity compensation program.
According to the footnote, this award is in the form of restricted stock units that vest 25% each year over four years from the grant date, subject to continued service. Following this grant, Nicholson beneficially owns 116,338 shares of Apellis common stock in direct ownership.
Apellis Pharmaceuticals’ chief financial officer, Timothy E. Sullivan, reported receiving an award of 58,140 shares of common stock on January 28, 2026 at a price of $0 per share, representing a restricted stock unit grant that vests 25% annually over four years, subject to continued service.
Following the award, he reports 152,041 shares of Apellis common stock held directly. An additional 60,396 shares are reported as indirectly held through The Timothy E Sullivan Irrevocable Trust of 2023, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Apellis Pharmaceuticals reported that its General Counsel, David O. Watson, received a grant of 55,986 shares of common stock on January 28, 2026, at a price of $0, described as a restricted stock unit award vesting 25% annually over four years, subject to continued service. Following this award, he directly beneficially owns 144,517 shares of common stock. He also reports indirect holdings of 10,000 shares in a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, for which he disclaims beneficial ownership except for any pecuniary interest.
Apellis Pharmaceuticals CEO Cedric Francois reported a new equity grant of 195,952 shares of common stock on January 28, 2026, awarded as restricted stock units at $0 per share. Following this grant, he directly holds 481,997 Apellis common shares.
The RSU award vests 25% each year over four years from the grant date, subject to continued service. Additional Apellis shares are held by several trusts, including The Cedric Francois Irrevocable Trust of 2023 - 2, The Cedric Francois Irrevocable Trust of 2023, The Francois Grossi Trust, and The Francois-DuBois Educational Trust, where Francois disclaims beneficial ownership except for any pecuniary interest.
Apellis Pharmaceuticals Chief Medical Officer Caroline Baumal reported a routine insider transaction involving company common stock. On January 22, 2026, she sold 2,797 shares of Apellis common stock at a price of $21.7654 per share. According to the footnote, these shares were sold specifically to cover tax withholding obligations arising from restricted stock units that were released on January 21, 2026.
After this sale, Baumal beneficially owned 86,527 Apellis shares, all held directly. The filing characterizes this as a tax-related sale rather than a discretionary open-market reduction in her overall ownership.
Apellis Pharmaceuticals insider activity: VP and Chief Accounting Officer James George Chopas reported a sale of Apellis Pharmaceuticals common stock mainly for tax purposes. On January 22, 2026, he sold 2,064 shares of common stock at a price of $21.7654 per share. According to the footnote, these shares were sold to cover tax withholding on Restricted Stock Units that were released on January 21, 2026. After this transaction, he continued to beneficially own 49,805 shares of Apellis common stock directly.
Apellis Pharmaceuticals reported an insider stock transaction by Chief Business & Strategy Officer Mark DeLong. On January 22, 2026, he sold 3,371 shares of Apellis common stock at $21.7654 per share. According to the disclosure, these shares were sold to cover tax withholding obligations related to restricted stock units that were released on January 21, 2026, meaning the sale was tied to equity compensation rather than an open-market liquidation of a larger position. After this sale, DeLong beneficially owned 78,353 shares of Apellis common stock.
Apellis Pharmaceuticals Chief Scientific Officer Pascal Deschatelets reported a sale of Apellis common stock in a Form 4 filing. On January 22, 2026, he sold 5,928 shares of common stock at a price of $21.7654 per share. According to the filing, these shares were sold to cover tax withholding obligations on restricted stock units that were released on January 21, 2026. After this transaction, Deschatelets directly beneficially owned 1,151,382 shares of Apellis common stock.